SciLifeLab

Calls for new project support in Chemical Biology and Drug Discovery
2026-01-30 12:00 - 13:00 (Europe/Stockholm) | Online event via Zoom
The Chemical Biology Unit (CBCS) and the Drug Discovery and Development (DDD) platform at SciLifeLab have calls out for projects.

CBCS is seeking projects in Chemical Biology that include assay development for small-molecule screening and profiling, as well as enabling chemistry.

For more information, please visit www.cbcs.se.

The DDD platform is looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest, including small molecules, antibodies, oligonucleotides and new modalities.

Some users and projects are at the intersection between chemical biology and drug discovery. This webinar aims to guide users to the call that best suits the needs of their project

Register here!

Organizer: the Chemical Biology Consortium Sweden and the Drug Discovery & Development platform

Exploring biology with small molecules and opportunities for early drug discovery
2025-09-05 12:00 - 13:00
Open call for project support within our service areas – from assay development and small molecule screening through drug profiling to medicinal/synthetic/organic and computational chemistry support.

Register to receive the zoom link

Call for new project proposals for drug discovery. DDD supports a project portfolio consisting of about 20 programs and we foresee a need to replenish our portfolio with 3-5 new programs in 2025. We are interested in programs with defined targets for diseases with medical needs using any therapeutic modality, e.g. antisense oligonucleotides, small molecules, antibodies and/or proximity-inducers.

flyer_webinar CBCS DDD 2025_2Download

Calls for new project support from chemical biology and genome engineering platform and the drug discovery & development platform
2024-08-15 11:00 - 11:45 | Online event via Zoom
The Chemical Biology and Genome Engineering platform and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects support.

The Chemical Biology unit looks projects proposals including including assay development, small molecule screening, drug profiling, and medicinal and computational chemistry. For more information, please visit www.cbcs.se.

The Chemical Biology and Genome Engineering platform are inviting project proposals aiming to explore compounds/drugs mechanism of action that harness the combined strengths of at least two platform units. If approved, these projects will gain cost-effective access to CBGE’s cutting-edge technologies

Both the above welcome proposals in all areas of biology not only in human health.

The DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest, including small molecules, antibodies, oligonucleotides and new modalities.

Some users and projects are at the intersection between chemical biology and drug discoveryhttps://ki-se.zoom.us/j/61032835991

Program:

1. Presentation of CBGE offerings

2. Presentation of the DDDp offerings

3. Q/A

Blending Chemistry and Biology to Enable Systems Pharmacology
2023-09-27 10:00 - 11:00 | Gamma 2 Lunchroom, SciLifeLab, Tomtebodavägen 23, Solna, Sweden
Patrick Aloy, Prof., Institute for Research in Biomedicine (IRB Barcelona)

Organizers

CBCS-KI and PhenoTarget Research Community Program

Join the seminar on Zoomhttps://ki-se.zoom.us/j/64473979770

Abstract

Big Data analytical techniques and AI have the potential to transform drug discovery, as they are reshaping other areas of science and technology, but we need to blend biology and chemistry in a format that is amenable for modern machine learning. In this talk, I will present the Chemical Checker (CC), a resource that provides processed, harmonized and integrated bioactivity data on small molecules. The CC divides data into five levels of increasing complexity, ranging from the chemical properties of compounds to their clinical outcomes. In between, it considers targets, off-targets, perturbed biological networks and several cell-based assays such as gene expression, growth inhibition and morphological profiles. I will also present the Bioteque, a resource of unprecedented size and scope that contains pre-calculated biomedical embeddings around 11 biological entities (e.g. genes, cells, tissues, disease, etc), derived from a gigantic knowledge graph, so that each entity can be described considering different contexts (e.g. interactions, expression, etc). With small molecule and biological bioactivity descriptors in hand, we now face a new scenario for chemical and biological entities where they both are translated into a common numerical format. In this computational framework, complex connections between entities can be unveiled by means of simple arithmetic operations. Indeed, we demonstrate and experimentally validate that these descriptors can be used to reverse and mimic biological signatures of disease models and genetic perturbations in vitro and in vivo, options that are otherwise impossible using chemical information alone.ReferencesDuran-Frigola et al. Extending the small molecule similarity principle to all levels of biology with the Chemical Checker. 2020. Nat Biotechnol. 38: 1087-1096.

Bertoni et al. Bioactivity descriptors for uncharacterized chemical compounds. 2021. Nat Commun. 12: 3932.

Pauls et al. Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models. 2021. Genome Med. 13:168.

Fernández-Torras et al. Connecting chemistry and biology through molecular descriptors. 2022. Curr Opin Chem Biol, 66: 102090.

Fernández-Torras et al. Integrating and formatting biomedical data in the Bioteque, a comprehensive repository of pre-calculated knowledge graph embeddings. 2022. Nat Commun. 13: 5304.

European Chemical Biology Symposium
2023-05-09 08:00 - 2023-05-11 17:00 | AstraZeneca, PGN Entrance, Pepparedsleden 5, Mölndal, 431 53
The free event will combine ELRIG’s inaugural meeting on Therapeutic OLIGOs with the 8th European Chemical Biology Symposium (ECBS) and will be held in Gothenburg, Sweden from May 9–11. Over the three days, academia, industry, and the vendor community will discuss recent advancements in two ultra-exciting areas of drug discovery and biological research: therapeutic oligonucleotides and chemical biology.

Speakers range from breakthrough therapeutic oligo pioneer Frank Bennet, to the vastly experienced Marie Vikstrom Lindholm of Silence Therapeutics.

Keynote speakers

Frank Bennett, Katherine Donovan, Steven Dowdy, Marie Wikstrom Lindholm and Shantanu Singh.

Presenters

Petr Bartunek, Tom Brown, Peter Crowley, Samir EL Andaloussi, Simon Elsässer, Alice Ghidini, Aurelie Goyenvalle, Peter Hagedorn, Emma Kay, Stefan Kubicek, Michael Kurczy, Pär Matsson, Cristina Mayor-Ruiz, Rui Moreira, Sílvia Osuna, Andrea Rentmeister, Chiara Saponaro, Sabine Sewing.

Read more

Chemical Biology Seminar Series
2022-12-14 15:30 - 17:00 | Air&Fire, SciLifeLab Stockholm, Tomtebodavägen 23A, Solna, Sweden
“TARGETING RIBOSOME BIOGENESIS IN CANCER”

Dimitris KanellisDept. of Medical Biochemistry and Biophysics, Karolinska Institutet“SYNTHETIC SWITCHES FOR DNA REPAIR – CONTROLLING ENZYMATIC FUNCTIONS AT WILL”Maurice MichelDept. of Oncology-Pathology, Karolinska Institutet

Date: Wednesday December 14

Time: 3.30 pm

Location: Air & Fire, SciLifeLab

The seminars are also available on Zoom.

https://ki-se.zoom.us/j/66622023014

Chemical Biology Seminar
2022-11-24 15:00 - 17:00 | Gamma 2 Lunchroom, SciLifeLab, Tomtebodavägen 23, Solna, Sweden
“DATA-DRIVEN HALLMARKS OF ACUTE MYELOID LEUKEMIA:

BIOLOGICAL, PROGNOSTIC AND THERAPEUTIC IMPLICATIONS”

Tom Erkers

Assistant professor, Dept. of Oncology-Pathology, Karolinska Institutet

“SYNTHETIC SWITCHES FOR DNA REPAIR –

CONTROLLING ENZYMATIC FUNCTIONS AT WILL”

Maurice Michel

Assistant professor, Dept. of Oncology-Pathology, Karolinska Institutet

Nov. 24 at 3.30 pm

Gamma 2 Lunch Room, SciLifeLab Stockholm

And on Zoom

https://ki-se.zoom.us/j/64941340588

Developing therapies for the inherited bone marrow failure syndrome diamond-blackfan anemia
2022-10-27 15:30 - 17:00 | Air&Fire, SciLifeLab Stockholm, Tomtebodavägen 23A, Solna, Sweden
Johan Flygare

Docent, MD and PhD, Department of Laboratory Medicine, Lund University

Host: Mikael Lindström, Docent and PhD

October 27 at 3.30 pm

Seminar room: Air & Fire

Organizers: CBCS-KI and PhenoTarget Research Community Program

Calls for new project support in chemical biology and drug discovery
2022-08-15 11:30 - 12:15 | Online event via Zoom
The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects.

CBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling, as well as enabling chemistry. For more information, please visit www.cbcs.se.

The DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest, including small molecules, antibodies, oligonucleotides and new modalities.

Some users and projects are at the intersection between chemical biology and drug discovery.This webinar aims to guide users to the call that best suits the needs of their project.

Registration
